We delivered strong growth in the second quarter, with double-digit year-over-year growth in our core business and mid-teens growth sequentially, said Tim Walbert, chairman, president and chief executive. February 14, 2023: The maker of Tepezza, Horizon Therapeutics, is seeking to have the Tepezza hearing loss claims against it dismissed under the doctrine of federal preemption. 8, 2023- Horizon Therapeutics plc (Nasdaq: HZNP) today announced second-quarter 2023 financial results. If you opt-out your email will still be collected for registration purposes. February 28, 2023: What a Tepezza hearing loss suit looks like. You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address. How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform. Successful treatments typically lead to new competitors but the expert doesn’t see any threats to Tepazza for at least five years.By accessing or using the AdisInsight platform you agree to the terms of use. The expert stopped offering his patients a chance to participate in a trial for a potential competitor, Immunovant’s RVT-1401, because he couldn’t recruit them because of the success of Tepezza. Regarding potential competition, Jefferies’ expert sees smooth sailing ahead for Tepezza. It's approaching $500,00 for his heaviest patients. But Jefferies’ expert puts the figure for his average-sized patient to be $350,000. Price is another potential hurdle. Upon its launch, Horizon estimated a six-month course of the drug would cost $200,000. ![]() RELATED: Horizon switched up strategy for Tepezza launch, moving quickly to DTC to reach eye disease patients The expert reports that 25% of his patients have built some skepticism about Tepezza. 22, 2023- Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive topline results from its randomized, double-masked, placebo-controlled Phase 3 clinical trial evaluating TEPEZZA for the treatment of TED in Japanese patients with higher levels of disease activity, as measured by clinical activity score (. Once you decide TEPEZZA ® (teprotumumab-trbw) is right for your patient, it’s easy to start their enrollment in Horizon By Your Side with the Patient Enrollment Form (PEF) and submit it using one of two convenient options. The most common are muscle cramps, nausea and diarrhea. And the source reported an “increasing call volume from other physicians-particularly endocrinologists and community doctors-seeking advice on treating TED patients with Tepezza."ĭespite the enthusiasm, the expert raised some caution flags because of side effects, at least one of which has impacted 80% of his patients. The expert noted an “amazing amount of public interest,” in the under-recognized disease, the analysts wrote. RELATED: Horizon’s Tepezza supply dwindles as manufacturer Catalent pivots to Warp Speed vaccinesĪdditionally, patient enrollment in April was the strongest month for Tepezza since its launch, management said.Īnother reason for the rapid rebound, according to the expert cited by Jefferies, is increased awareness of Tepezza in the medical community, as well as a highly effective ad campaign. Catalent resumed production in April after the FDA authorized Horizon to manufacture more vials per batch.Įarly this month at the Jefferies Healthcare Conference, Horizon management noted that 75% of disrupted patients had either restarted or were scheduled to resume treatment versus a 50% figure from the previous month. The drug, which carries a price tag of $14,900 per vial, registered sales of more than $800 million last year, with double-digit growth in the fourth quarter despite pandemic disruptions.īut Horizon and patients felt the effects of the supply disruption particularly during first quarter of this year, when sales plummeted to $2.1 million. Seven to 10 are queued up for infusion and four have been denied insurance. Of the 55 to 60 prescriptions the doctor has written for Tepezza so far, 43 patients have been infused, the analysts wrote. “The key opinion leader has witnessed little to no regression in TED symptoms despite protracted delay between infusions.” Nearly all of the doctor’s patients have resumed therapy since the supply disruption, “but the time to restart has been variable,” Jefferies analysts wrote.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |